Innovative Toxicity Assays of Pollutants, Therapeutics, and Drugs (SBIR R43/R44) | Apply Online

Frequently Asked Questions (FAQs)

What is the NIH funding opportunity PA-09-006 about?

PA-09-006, titled "Innovative Toxicity Assays of Pollutants, Therapeutics, and Drugs (SBIR R43/R44)," is an NIH Small Business Innovation Research (SBIR) grant opportunity focused on creating improved tools to detect, measure, or predict toxic effects from chemicals and medical products. The emphasis is on moving toxicity testing toward approaches that are faster, more cost-effective, and more predictive of organ-specific harm, with an expectation that new methods will be standardized and validated for credible, consistent use.

Who is eligible to apply for this opportunity?

Eligibility is limited to small business concerns, because this is an SBIR funding opportunity (R43/R44). No additional eligibility categories are described in the provided information.

What types of projects are a strong fit for PA-09-006?

The best fit is a small company developing new assay platforms, predictive models, organotypic culture systems, screening batteries, or integrated testing strategies that connect exposure to specific toxicity outcomes. Projects that include a clear path to standardization and validation, and that support higher-throughput decision-making using molecular and/or computational endpoints, align strongly with the stated goals.

What is the overall goal NIH is trying to achieve with this FOA?

NIH is trying to accelerate innovation in toxicity testing by supporting tools and strategies that can reliably indicate organ-specific toxicity, while also pushing applicants to demonstrate rigor through standardization and validation. The aim is to improve how toxic effects are detected, quantified, and predicted across research and development settings.

What kinds of toxic effects or organ systems are included in the scope?

The FOA explicitly mentions a broad range of toxicities and organ systems, including ocular and dermal toxicity; hematotoxicity; cardiotoxicity; gastrointestinal toxicity; hepatotoxicity (liver); nephrotoxicity (kidney); bladder toxicity; ototoxicity (hearing-related) and olfactory loss; neurotoxicity; pulmonary toxicity; endocrine toxicity; and toxicity affecting pancreatic beta cells.

Does the FOA cover both acute and chronic toxicity?

Yes. The scope includes toxicities arising from acute exposure (short-term, potentially higher-dose) as well as chronic exposure (long-term, potentially lower-dose).

What types of agents or exposures are relevant under this announcement?

The FOA covers a wide range of agents, including industrial or environmental pollutants, general chemicals, biologics, therapeutic molecules, and drugs.

Is this FOA relevant only to drug developers?

No. Based on the described scope, it can be relevant to companies working in drug development, environmental health, consumer product safety, and advanced in vitro or in silico testing platforms, as long as the work supports detecting, measuring, or predicting toxic effects.

What is meant by “innovative toxicity assays” in this context?

In this announcement, innovative toxicity assays refers to new testing methods or strategies that improve the ability to identify organ-specific toxic effects and that move beyond slower, more expensive, or less predictive approaches. NIH also signals that innovation alone is not enough; the methods should be standardized and validated so they can be used reliably and credibly.

Does NIH require that methods be standardized and validated?

Yes. A central theme is that applicants are expected not only to invent new methods, but also to standardize and validate them so they can be used consistently and credibly in research and development.

Are higher-throughput toxicity screening approaches encouraged?

Yes. The FOA encourages modern, higher-throughput approaches, especially those that use molecular endpoints and computational strategies.

What specific “modern” approaches are explicitly encouraged?

The FOA calls out computer modeling, proteomics, genomics, and epigenomics, as well as development of “virtual tissues” and three-dimensional organ models for toxicity evaluation.

What are “virtual tissues” in the context of this FOA?

“Virtual tissues” is described as computational or integrated modeling frameworks intended to mimic tissue behavior or predict toxicity outcomes.

Are three-dimensional (3D) organ models within scope?

Yes. The FOA encourages development of 3D organ models for toxicity evaluation, aligning with more physiologically relevant in vitro systems that may better replicate organ-level responses than traditional two-dimensional cell cultures.

Does this FOA include models beyond classic toxicity assays?

Yes. In addition to organ toxicity assays, NIH signals interest in developing, standardizing, and validating new models related to arthritis, convulsion, infection, and shock.

What funding mechanisms are used for PA-09-006?

This is an SBIR opportunity using the NIH R43 (Phase I) and R44 (Phase II) mechanisms.

What application types are accepted under this SBIR announcement?

The FOA accepts Phase I, Phase II, and Fast Track applications.

What is the difference between Phase I, Phase II, and Fast Track as described here?

Phase I generally supports early feasibility and proof-of-concept work. Phase II supports more advanced development and validation. Fast Track is intended to accelerate the transition from Phase I to Phase II for projects with a strong development plan.

Is there a companion opportunity under STTR?

Yes. The announcement notes a companion FOA of identical scientific scope under the Small Business Technology Transfer (STTR) program, PA-09-007, which may be relevant for teams planning a formal collaboration with a nonprofit research institution under STTR rules.

Is cost sharing or matching funding required?

No. The opportunity does not require cost sharing or matching funds.

What type of grant program is this categorized as?

It is categorized as a discretionary grant program offered by the National Institutes of Health.

Is PA-09-006 still open for applications?

No. Based on the provided dates, it is a historical FOA. The original posting date was October 7, 2008. The original and current closing date was September 7, 2009, and the archive date was October 8, 2009.

Which NIH/CFDA program areas are associated with this FOA?

The listing is tied to multiple CFDA program areas reflecting broad relevance, including environmental health (93.113), vision research (93.867), cardiovascular diseases (93.837), arthritis and musculoskeletal and skin diseases (93.846), diabetes/digestive/kidney diseases (93.847), deafness and communication disorders (93.173), nursing research (93.361), and other biomedical research and research training categories (including 93.859 and 93.389).

What kinds of end users or settings does NIH appear to have in mind for the outputs?

NIH emphasizes use that is consistent and credible in research and development settings. The description also points to real-world relevance for evaluating pollutants and therapeutics, and for supporting higher-throughput decisions using molecular and computational endpoints.

What would make an application especially aligned with NIH’s priorities in this FOA?

Based on the description, strong alignment comes from (1) clear innovation in toxicity detection/measurement/prediction, (2) an explicit plan or pathway to standardization and validation, (3) relevance to real-world exposures involving pollutants and/or therapeutics, and (4) support for higher-throughput screening or decision-making, particularly with molecular endpoints and computational strategies.